We’re excited to announce the latest updates to Glooko Web 25.2 and Mobile 6.12, which are designed to help healthcare providers and people with diabetes by streamlining workflows, providing a new population management dashboard to triage at-risk patients and review population-level metrics, improving data visualizations, and giving care teams more powerful data from compatible devices to enhance diabetes management.

Introducing the New Clinic Dashboard

In this release, we launched a new clinic dashboard in the U.S. designed to give healthcare professionals at-a-glance insights into population health trends and clinic management metrics. This enhancement makes it easier to interpret complex data and guide decisions and clinic strategy more efficiently across care teams.

Other new clinic dashboard highlights include:

• Population Metrics: This section gives a single, concise, and organized view of the clinic’s total patient population, patients monitoring blood glucose, and those with activated accounts using key engagement and monitoring metrics.
• CGM Patient Risk Stratification: This dashboard, modeled after the Timely Interventions for Diabetes Excellence (TIDE) Dashboard, gives healthcare providers a streamlined view of their patient population, ranked by risk level using key glucose metrics and CGM data only. Care teams can identify risk levels using Time in Range, Time Below Range, and other key CGM indicators to prioritize care.
• Engagement Metrics: This section helps healthcare providers spot engagement gaps within their patient population over the past 90 days and take action to get more patients connected and syncing their devices with Glooko. With more synced health data, care teams can make more informed treatment decisions.

Banner Notification for Missing MRN

Glooko’s connected care platform prioritizes deep EHR integration to bring actionable diabetes data into the systems clinicians already use. To help maintain EHR data integrity and ensure patient matching is seamless, Glooko introduced a clear dismissible banner on the patient dashboard to notify clinicians when a Medical Record Number (MRN) is required but missing.

Tandem Basal Profile Switches

A new icon in DayView and WeekView on the Glooko diabetes management platform identifies when a patient changes their Tandem Personal Profile to give better context for insulin delivery.

GLP-1 Dose Enhancements

GLP-1 doses will now be displayed in the Glooko Web and Mobile software with improved messaging and clinical disclaimers. Healthcare professionals will now receive relevant dose range notifications while also providing precise dose information to support better oversight and patient adherence, while patients will see exact GLP-1 doses up to two decimal places as injected.

Device Type Display in PDFs

Glooko will now display controller device types in the PDF Settings Report, helping clinicians more clearly understand where data originated for users of Omnipod® 5 and other select devices. The report will specifically say on a clear device label the upload method (e.g., Android, iOS, Locked Down Controller) used by the patient.

Updated Insulin Statistics Design

The Glooko Mobile App’s insulin card has been redesigned to enhance clarity and consistency, particularly benefiting users with insulin pump data. This update aims to improve the understanding of insulin averages and minimize confusion between pump and total insulin values by displaying data in one unified insulin card.

More Information on the Latest Glooko Release

For more detailed information about these new features intended to enhance clinical practices and transform diabetes, be sure to check the full release notes on our Glooko Support page.

The NHS’s ambitious “Fit for the Future: 10 Year Health Plan for England” outlines a bold vision for the future of healthcare in the country — one that is digitally advanced, community-focused, and prevention-driven. It’s a plan designed to move healthcare from a reactive, hospital-centric model to a proactive, patient-empowering system utilising cutting-edge technologies. Within this transformative agenda, Glooko’s diabetes management platform stands out as an excellent example of how digital health solutions can directly support these crucial goals.

From Analogue to Digital: Empowering Patients and Streamlining Care

At the heart of the NHS’s plan is a commitment to becoming “digital by default.” This means harnessing technology to make healthcare more accessible, efficient, and patient-friendly.

Imagine a world where your health data, whether from your BGM, CGM, insulin pen, or activity tracker, is all in one place. That’s what Glooko offers through its integrations with more than 200 diabetes and health monitoring devices, including wearables, a future standard in the NHS by 2035. By centralising this vital information, it empowers people living with diabetes to take a more active role in managing their diabetes and saves them time by not having to juggle multiple apps or manually record readings.

For healthcare professionals, Glooko centralises health data from their patients into a single platform, helping create the “single, secure and authoritative account of their data” that the NHS aims for. To help reduce time-wasting administrative tasks, streamline workflows, and allow clinicians to have more efficient appointments focused on providing quality care, Glooko is expanding its capability to sync with electronic health record (EHR) systems across England and the rest of Europe. When all the relevant data is at their fingertips and seamlessly flowing between clinical records and the Glooko platform, everyone on the care team, including diabetologists, diabetes specialist nurses, registered dietitians, and general practitioners, can make more informed clinical decisions using our diabetes technology.

With our commitment to safeguarding confidential personal information and handling patient data properly, our diabetes management platform and our company’s practices meet the NHS’s data security standards outlined in the Data Security and Protection Toolkit. We align with the NHS’s requirements for all organisations with access to their patient data and systems.

From Hospital to Community: Enabling Remote Monitoring and Personalised Care

The NHS plan emphasises shifting care away from hospitals and into local communities and even patients’ homes. Glooko is instrumental in making this a reality for diabetes care with its remote patient monitoring capabilities.

This innovative feature of our diabetes software for healthcare providers means fewer trips to the hospital for routine check-ups and more proactive management of diabetes from the comfort of a patient’s home. This not only improves convenience for people living with diabetes but also helps to alleviate pressure on acute hospital services and supports the development of community-based models like “Neighbourhood Health Centres.”

The Glooko connected care platform offers powerful population health analytics. This allows hospitals to view trends and manage their entire patient population more effectively, aligning with the NHS’s goal of preventing illness and managing long-term conditions on a larger scale. The detailed insights provided by Glooko’s data can also support the creation and monitoring of highly personalised care plans, moving closer to the NHS’s goal of offering personal health budgets and tailored support for complex needs like diabetes.

From Sickness to Prevention: Proactive Management and Improved Outcomes

A core tenet of the NHS’s 10 Year Health Plan is a strong focus on prevention and early intervention.

By providing continuous diabetes and related health data and insights, Glooko helps healthcare providers identify potential issues and risks before they escalate. This allows for proactive intervention, which can significantly reduce the likelihood of diabetes-related complications, improving long-term health for patients.

And Glooko isn’t just about data; it’s about demonstrable results. The diabetes management platform has a track record of improving clinical outcomes, including reduced HbA1c levels. These outcomes directly align with the NHS’s aspirations for better health for the population, reduced demand on acute services, and a more sustainable healthcare system.

A Healthier Future for People with Diabetes

We want the NHS 10 Year Health Plan to deliver real improvements for people with diabetes and their care teams. Glooko is more than a diabetes management tool; we’re a strategic partner committed to helping the NHS deliver better care for all patients regardless of wherever they live and whatever they earn.

By accelerating digital transformation, enabling care at home, and championing proactive diabetes management, Glooko is helping build a more efficient, patient-centered, and digitally advanced healthcare system.

With innovative solutions and preferred vendors like Glooko, the NHS is well-equipped to meet the challenges and opportunities ahead as they usher in the future of healthcare in England.

Glooko is excited to showcase how our connected care platform is transforming diabetes care and simplifying diabetes management at the 61st Annual Meeting of the European Association for the Study of Diabetes (EASD 2025) in Vienna, Austria, from 15 to 19 September 2025.

At booth C6.07 of the international diabetes conference, Team Glooko will provide partners, industry thought leaders, and healthcare professionals with the opportunity to experience our latest innovations.

• Glooko in Action: We’ll provide live demonstrations of the Glooko Web and Mobile App uniquely designed to address the growing complexities in diabetes care and improve health outcomes of people living with diabetes. With Glooko, healthcare providers can simplify diabetes management, reduce administrative burden, and improve clinical workflows to focus more on delivering care and less on managing data.
• Hedia Diabetes Assistant: Glooko’s recent collaboration with Hedia, a trusted bolus calculator already available in the U.K. and Sweden, enhances precision and efficiency for multiple daily insulin dosing. The new integration offers personalised recommendations and streamlined diabetes management for people living with diabetes while providing healthcare professionals with comprehensive insights through Glooko.
• Industry-Leading Device Compatibility: Through our partnerships, Glooko enables people with diabetes to seamlessly sync and analyze health data from more than 200 diabetes and health monitoring devices. This extensive ecosystem, including CGMs, BGMs, insulin pens and pumps, and health and wellness apps, allows for better collaboration with care teams and improved health outcomes.
• EHR Integrations: Glooko is working to expand its capability to sync with EHR systems across Europe, supporting a smoother flow of data between clinical records and our diabetes software. These integrations are designed to help streamline workflows and reduce administrative tasks, enabling healthcare providers to spend more time focusing on efficient, data-driven patient care.

To meet with one of our experts at EASD 2025, schedule a meeting.

We look forward to seeing you in Vienna!

Managing diabetes care has become increasingly complex for clinics, hospitals, and health systems. With a growing number of people living with diabetes relying on multiple devices — glucose meters, continuous glucose monitors (CGMs), insulin pumps, and wearables — healthcare providers face the challenge of piecing together critical data from siloed systems. This fragmentation not only consumes valuable time, but hinders patient care.

At Glooko, we know device integration is the key to solving these challenges and transforming diabetes management. As a market leader in device compatibility, EHR integration, and interoperability, Glooko increases efficiency of clinical workflows by streamlining administrative tasks, enhances patient engagement, and helps deliver better outcomes.

The Challenges of Fragmented Diabetes Management

For healthcare providers, piecing together data from various devices and platforms and apps can feel like an endless puzzle. Without device integrations, clinics and health systems face:

• Disconnected Data: Patient data is scattered across incompatible platforms and apps, making it difficult to understand a patient’s holistic health.
• Inefficient Workflows: Healthcare providers must spend time manually entering or retrieving data instead of focusing their time and expertise to support their patients in achieving better health.
• Limited Patient Engagement: Patients often struggle to track their progress with so many different tools and apps, becoming overwhelmed and losing hope in their ability to make meaningful change.

These challenges contribute to missed opportunities for timely interventions that drive better health outcomes.

How Glooko’s Compatibility Brings Clarity to Diabetes Care

Glooko simplifies diabetes management by integrating data from more than 200 diabetes and health monitoring devices — including Abbott’s FreeStyle Libre CGMs in the U.S. — into a single, user-friendly platform.

Here’s how Glooko’s device compatibility transforms care:

• Data Integration and Interoperability: Glooko consolidates glucose levels, insulin usage, and lifestyle behaviors such as diet and physical activity, giving healthcare providers a holistic view of patient health. Care teams can easily access patient data from a centralized platform.
• Remote Monitoring Capabilities: Healthcare providers can track patient trends and progress between visits, ensuring timely adjustments to care plans and reducing unnecessary appointments and emergency room visits.

Not all devices are available in every country where Glooko is available. The product images are for illustrative purposes only. Not actual patient data. The sensor housing, FreeStyle, Libre, and related brand marks are marks of Abbott and used with permission. Important Safety Information: For full FreeStyle Libre systems safety information, please visit https://www.freestyle.abbott/us-en/safety-information.html.

The Many Benefits of Integration for Clinics, Hospitals, and Health Systems

Our industry-leading device compatibility benefits clinics, hospitals, and health systems by streamlining workflows and improving decision-making through a comprehensive view of patient data. With greater efficiency, care teams can focus more on patient care and expand their reach to serve more individuals in need.

• Streamlined Workflows: Staff spend less time on administrative tasks and more time on what they do best: educating and providing care to their patients.
• Improved Decision-Making: A comprehensive view of patient data allows care teams to create more personalized and effective treatment plans.
• Expanded Clinical Footprint: With more time, clinicians can help more patients in need.

To enable more meaningful data insights, Glooko also seamlessly integrates the health data from their patients’ diabetes and health monitoring devices directly into leading EHR systems, eliminating manual uploads and platform switching and reducing administrative burden.

The Key Benefits of Device Integrations for People Living with Diabetes

Glooko’s device integrations benefit people living with diabetes by simplifying their experience and empowering self-management through centralized data, reducing app overload and supporting informed health decisions.

• Simplified Experience: With integrated data, patients no longer need to juggle multiple apps and passwords, or manually report their glucose levels to their provider.
• Empowered Self-Management: Patients can log meals, exercise, and medications directly in the Glooko app, helping them understand how their choices impact their health.

Proven Results Backed by Global Expertise

Glooko has more than a decade of experience integrating diabetes and health monitoring devices worldwide, supporting millions of people living with diabetes. Glooko’s connected care platform, backed by real-world evidence, delivers the reliability, scalability, and insights clinics, hospitals, and health systems need to stay ahead in diabetes care, setting a new standard.

Simplify Diabetes Care with Glooko

The complexity of diabetes management doesn’t have to hold your clinic, hospital, or health system back. By choosing Glooko, you can eliminate data fragmentation, enhance patient care, and create a more efficient, streamlined experience for healthcare providers and people living with diabetes.

Schedule a personalized demo of our digital health platform today and see how your patients’ health data can be integrated directly into your EHR system.

As a leader in diabetes management, Glooko offers an intelligent connected care platform that allow people with diabetes and their healthcare providers to review, analyze, and evaluate data from many different types of diabetes devices, including blood glucose meters (BGM), continuous glucose monitoring (CGM) systems, insulin pumps, smart pens, and fitness apps.

With Glooko’s digital health solution allowing users to view and analyze CGM and insulin data in one place, we have the ability to work with hybrid closed loop systems, a technology — often known as an artificial pancreas — that automates many of the daily decisions of people living with Type 1 diabetes who use an insulin pump and CGM that communicate with each other.

Innovative hybrid closed loop systems take readings from an individual’s CGM and use an algorithm to automatically tell the insulin pump how much insulin to deliver to keep blood glucose levels stable around the clock.

How Glooko integrates with hybrid closed loop systems

Our digital health platform, used by over 10,000 clinics in more than 30 countries, syncs via the cloud with leading diabetes CGMs and insulin pumps in hybrid closed loop systems to automatically present data around glucose levels, basal rates and more to patients and their care teams via graphically-oriented reports that can help recognize trends, so they can take action to improve their health outcomes.

The hybrid closed loop systems that currently sync with Glooko include:

• mylife Loop (CamAPS FX and Ypsomed)
• Tandem Control-IQ
• Insulet Omnipod 5
• Dana CamAPS® FX

Depending on the brands of the insulin pump and CGM, different methods of syncing via cloud are required to view data in Glooko from hybrid closed loop systems.

Like any great technology, people living with diabetes using a closed loop system still must check to ensure it is working and must count carbohydrates to give the system the correct bolusing data before food consumption. This is where the Glooko Mobile App’s food tracker can be used to track nutrition by searching the food database, using voice capture, or scanning a barcode (in select countries).

Benefits of using hybrid closed loop systems with Glooko

There are many benefits of using hybrid closed loop systems alongside Glooko for patients, including:

• Major changes in treatment that reduce daily burdens and mental stress
• More time with glucose levels in range with less effort
• The ability to visualize blood glucose and insulin data in clear graphs that make it easier to understand automatic boluses and basal rates

There are also many benefits of using hybrid closed loop systems alongside Glooko for care teams, including:

• An increased monitoring of patients with diabetes who are using closed loop systems
• Strengthening their connection with their patients
• Better management of fluctuations in patients’ glucose levels
• Easier interpretation of patient data around basal rate, automatic vs. manual mode and automatic boluses

The future of hybrid closed loop systems

Hybrid closed loop systems in diabetes care are advancing toward more automation, intelligence, and accessibility. These systems are on a path toward becoming fully closed loop systems that will make managing diabetes more automated, adaptive, and accessible, allowing users to focus less on their condition and more on living life.

As the systems evolve, so will Glooko. With the regular introduction of new hybrid closed loop systems, Glooko will continue to partner with leading device manufacturers to integrate their platforms with our digital health solution.

For more information about using a hybrid closed loop system, consult with your healthcare team and explore resources from the Breakthrough T1D, Diabetes UK, and NHS England.

At Glooko, we empower certified diabetes care and education specialists (CDCES) by equipping them with the tools needed to help individuals with Type 1, Type 2, gestational diabetes, and prediabetes better manage their condition and reduce the risk of complications.

Our connected care platform offers remote patient monitoring, compatibility with more than 200 diabetes and health monitoring devices, and easy-to-read reports. With EHR integrations to streamline clinical workflows and population health dashboards, CDCES professionals can proactively identify trends, tailor care plans, and help improve health outcomes — making diabetes care and education more efficient, data-driven, and impactful.

If you’re a CDCES planning to attend the Association of Diabetes Care & Education Specialists’ ADCES25 in Phoenix, Team Glooko wants to meet you at booth #1131 to share the latest updates to our innovative diabetes management platform and mobile app and give you the opportunity to see how we’re transforming diabetes care.

Some of the exciting features and happenings that you can expect to see at our booth:

• Ask An Expert: Our booth will host Glooko Senior Director of Clinical Transformation Trisha Martinez, MBA, RN, BSN, an accomplished clinician, who will share best practices for how CDCESs can educate people living with diabetes to use Glooko to better manage their condition. Our resident clinical expert will be on-site to hear feedback, tips, and tricks for using our connected care platform.
  • Friday, August 8: 9:30-10:15 a.m. and 12:15-2:15 p.m.
  • Saturday, August 9: 9-9:45 a.m., 11:45-1 p.m., and 3-4 p.m.
• Glooko Web and Mobile App: We’ll provide live demos of Glooko, our cutting-edge connected care platform designed to simplify diabetes management and make it easier for people with diabetes to input, view, and understand their health data. Mobile app users can also take advantage of the innovative food tracker feature to easily log their food intake and view their food data alongside data from compatible devices, medications, and exercise. Best of all, the synced data can be securely shared with care teams to stay on track between appointments!
• New Clinic Dashboard: This summer, we’ll launch a new clinic dashboard in Glooko that provides a high-level view of a patient population and program performance across key areas. The Population Metrics panel tracks total patients, CGM use, and activation rates — updated every 14 days — to highlight trends and engagement gaps. CGM Risk Stratification uses CGM data to rank patients by clinical risk, helping prioritize care. Engagement Metrics show where patients are in their onboarding journey and how they sync data, enabling staff to focus outreach and improve engagement efforts.
• EHR Integrations: Glooko seamlessly integrates with leading EHR systems to securely consolidate diabetes data in one place, removing the need to switch platforms or manage multiple logins. This feature allows healthcare providers to work more efficiently within a single interface that offers a comprehensive view of each patient’s health data.
• Latest Device Compatibility: Glooko now integrates with Abbott’s FreeStyle Libre CGMs in the U.S., offering real-time glucose and lifestyle data in one platform, empowering people with diabetes to take better control of their health, and enabling healthcare providers to make more informed, data-driven decisions.

To meet with one of our experts at ADCES25, schedule a meeting.

See you in Phoenix!

The product images are for illustrative purposes only. Not actual patient data. The sensor housing, FreeStyle, Libre, and related brand marks are marks of Abbott and used with permission. Important Safety Information: For full FreeStyle Libre systems safety information, please visit https://www.freestyle.abbott/us-en/safety-information.html.

In late June, Glooko was proud to participate in the American Diabetes Association’s 85th Scientific Sessions in Chicago. We had the opportunity to connect with healthcare professionals, device partners, and diabetes community leaders to advance our digital health platform as we continue to power smarter, more efficient diabetes care.

From demonstrating our best-in-class EHR integrations that help simplify clinical workflows to sharing how our connected care solution integrates with more than 200 diabetes and health monitoring devices to drive more informed insights and better health outcomes, our presence at American Diabetes Association’s 85th Scientific Sessions was all about innovation and collaboration.

We were especially excited to host attendees at our Product Theater, where Glooko clinical experts Mark Clements, M.D., Ph.D., and Trisha Martinez, M.B.A., B.S.N., R.N., highlighted the impact of Glooko’s seamless EHR integration assets, tools, and capabilities that help streamline workflows, deliver actionable insights, and better manage patient populations with diabetes. Attendees also received early access to the 2025 Glooko Global Diabetes Report, which features a comprehensive look at how real-world data can drive better outcomes in diabetes care and help shape a smarter, more connected future of diabetes management.

Key ADA 2025 Takeaways from Team Glooko

	Mike Alvarez, CEO, Glooko: “The energy at ADA this year was incredible. I think this clearly signals how fast-moving innovation is in diabetes care. We had so many great conversations with clinicians and partners energized by what Glooko is bringing to the table — and we’re just getting started.”
	Rich Glenn, President, Connected Care, Glooko: “Participating in the ADA’s 85th Scientific Sessions reaffirmed the critical role Glooko plays in advancing connected care. Engaging with healthcare leaders, partners, and innovators gave us valuable insights to continue evolving our platform and ensuring we remain at the forefront of delivering smarter, more efficient diabetes management tools for healthcare providers and people living with diabetes.”
	Trisha Martinez, Senior Director, Clinical Transformation, Glooko: “The event reinforced the importance of data architecture that supports enterprise-level clinical reporting and delivers segmented insights to large health systems. CGMs continue to show promise, and there’s exciting potential for similar innovations in kidney and liver testing that could be tied to outcomes, population health, and prevention of chronic complications. Outpatient tech is evolving, potentially strengthening ties to hospital services. It’s also clear that demonstrating outcomes and integrating more services into the Glooko platform is key to enabling comprehensive disease management.”
	Rachel Beecham, Regional Vice President, Connected Care, South Central, Glooko: “Having the opportunity to spend time with people living with diabetes and their caregivers provided a meaningful perspective on the daily challenges they face and the care they require — deepening my sense of purpose and strengthening the mission behind our work at Glooko.”
	Adam Greenwald, Senior Customer Success Manager, Southwest, Glooko: “As a longtime Glooko employee, the annual American Diabetes Association event enabled me to continue to deepen my diabetes industry knowledge by exploring new cutting-edge diabetes technologies and strengthening connections with my peers, thought leaders, and customers.”

What’s Next? Connect with Team Glooko

Interested in learning more about what Glooko’s diabetes management platform has to offer your hospital, health system, or clinic? Schedule a personalized demo.

This is not part of the 85th Scientific Sessions as planned by the American Diabetes Association®. This content is neither sponsored nor endorsed by the American Diabetes Association®. This content does not qualify for continuing medical education (CME) credit.

The Glooko 2025 Global Diabetes Report offers a comprehensive look at how real-world data can drive better outcomes in diabetes care. Powered by billions of data points across 30+ countries, this report uncovers meaningful trends in glycemic management, technology adoption, and behaviors among people living with Type 1, Type 2, and gestational diabetes.

From the rise of remote monitoring to the impact of advanced technologies like Continuous Glucose Monitors (CGMs) and Automated Insulin Delivery (AID) systems, this report explores how personalized insights can be used to better inform personalized care, predict risk, and guide clinical decision-making.

Whether you’re a clinician, researcher, or innovator in diabetes management technology, this report highlights how data can be turned into action — helping to shape a smarter, more connected future of diabetes management.

Download the report

At Glooko, we are committed to simplifying diabetes insights and management for people living with diabetes and healthcare providers alike. That’s why our platform is compatible with more than 200 diabetes and health monitoring devices and growing.

As a company, we could not be more pleased to share that we recently expanded our capabilities to integrate with Abbott’s FreeStyle Libre CGMs in the United States. This integration brings glucose data to more clinics and health systems in our all-in-one solution for diabetes management.

This milestone is more than just a technological advancement — it’s about empowering people with Type 1, Type 2, and gestational diabetes, as well as prediabetes, to become active owners in their health. By combining the precision of Abbott’s FreeStyle Libre CGMs with Glooko’s comprehensive platform, we can provide people living with diabetes and their care teams, including endocrinologists and nurses, with a unified, holistic view of diabetes management and irrefutable information.

From glucose trends to lifestyle behaviors like diet and physical activity, this latest integration ensures that critical insights are easily accessible when and where they are needed most. For healthcare providers and health systems, this means the ability to seamlessly access and analyze patients’ CGM data through Glooko and established electronic health record (EHR) solutions, more informed decision-making, and improved patient outcomes. For people living with diabetes, it means greater confidence in their care and health.

As the number of people with diabetes continues to grow, the need for seamless, data-driven solutions has never been greater. Our new integration with Abbott’s FreeStyle Libre CGMs represents a significant step forward in delivering better, more connected care. This partnership is sure to have a positive impact on the millions of people who rely on FreeStyle Libre CGMs and Glooko.

In the United Kingdom, diabetes technology has rapidly advanced over the past two decades, with platforms like Glooko playing a central role in simplifying care and management.

In honor of Diabetes Week U.K. (9 June to 15), we’re taking a look at the state of diabetes, technology designed to better manage the condition, and the outlook on the evolution of diabetes care and technology.

The State of Diabetes in the United Kingdom

Diabetes is a significant public health concern in the U.K. According to Diabetes U.K., more than 5.8 million people are currently living with the condition. Of these, approximately 4.6 million have been diagnosed and an estimated 1.3 million people may be living with undiagnosed Type 2 diabetes.

Of those diagnosed with diabetes in the U.K., Type 2 diabetes accounts for approximately 90% of cases. While risk factors for Type 1 diabetes include family history and the presence of other autoimmune conditions, Type 2 diabetes risk is heightened obesity, family history, a history of gestational diabetes, specific medications, and other factors.

To address the growing prevalence of diabetes and support those affected, the National Health Service (NHS) offers various education programs aimed at empowering individuals with the knowledge and skills necessary to manage their diabetes effectively, improve health outcomes, and reduce the risk of complications.

For individuals with Type 2 diabetes, programs like DESMOND (Diabetes Education and Self-Management for Ongoing and Newly Diagnosed) and the X-PERT Diabetes Programme provide education on managing the condition through lifestyle changes and self-monitoring. For those with Type 1 diabetes, the DAFNE (Dose Adjustment For Normal Eating) program offers guidance on insulin management and dietary considerations and Digibete helps young people, families, and communities better manage Type 1 diabetes. Additionally, the VICTOR program is designed for adults with Type 2 diabetes who are on insulin therapy and focuses on adjusting insulin doses in response to routine changes.

Diabetes Technology Today

In the U.K., diabetes technology is advancing quickly with Glooko helping streamline data management across compatible diabetes and health monitoring devices, including:

• Hybrid closed loop (HCL) systems, which combine continuous glucose monitoring (CGM) with insulin pumps to automatically adjust insulin delivery based on real-time data.
• Devices like Tandem t:slim X2 require cable downloads, while mylife Loop powered by CamAPS® FX and Omnipod® 5 use cloud-to-cloud integration.
• CGMs provide glucose trends and alerts and are often compatible with pumps and cloud platforms.
• Abbott FreeStyle Libre CGMs data can be seen within Glooko through the upload of data from HCL-compatible insulin pumps.
• Fitness and health monitoring apps can track steps, weight, and blood pressure.
• Smart pens and connected pens allow for remote or in-clinic dose tracking.

Transforming Diabetes Care in the United Kingdom with Glooko

Across the country, more than 85,000 people living with diabetes use Glooko’s digital health platform to manage their diabetes and more than 500 clinics are using Glooko to provide better care to their patients.*

Through our data*, we identified key metrics for time in range for people with Type 1, Type 2, and gestational diabetes in the U.K. using Glooko during 2024.

Today, there is an increased interest in TITR and TIR as a result of the recent technology available for managing diabetes. The Glooko diabetes data management platform helps healthcare providers monitor TIR and TITR to improve glycemic outcomes for people living with diabetes, bringing data from multiple devices into one platform with comprehensive charts and graphs. It ensures consistent data access — even without connected devices — and meets high standards for data protection, including GDPR compliance, to support safe, effective, and standardised diabetes care.

The Future of Diabetes Care in the United Kingdom

The future of diabetes care in the U.K. lies in advancing technology and deeper collaboration. Recent key developments include moving towards fully closed loop systems, integrating AI-enabled personalized insights, and aligning diabetes management with weight loss medications. Continued innovation will help provide more tailored, effective treatment options for people living with diabetes.

Progress also depends on strong partnerships with leading diabetes organisations like the Diabetes Technology Network (DTN-UK) and Diabetes National Networking Forums (NNF).

The future of diabetes care in the U.K. lies in advancing technology and deeper collaboration. Recent key developments include moving towards fully closed loop systems, integrating AI-enabled personalized insights, and aligning diabetes management with weight loss medications. Continued innovation will help provide more tailored, effective treatment options for people living with diabetes.

By showcasing technologies such as hybrid closed loop systems at local events from these leading organisations and through initiatives like our Academy program, a collaboration between Glooko and the Association of British Clinical Diabetologists(ABCD)/DTN-UK providing free education for medical professionals in the U.K., we help educate, support, and empower both clinicians and people living with diabetes across the country.

*Internal Glooko data; based on active Glooko users that synced during 2024